ClinicalTrials.gg
Active, not recruitingNCT05312879AMPLITUDEUpdated Oct 26, 2026

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

A Phase 2/3 interventional study of VX-147 and Placebo in Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 314 sites in 13 countries. Open to participants aged 10 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruitingEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
522
Allocation
Randomized
Ages
10 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

02

Conditions studied

  • Proteinuric Kidney Disease

Keywords

  • APOL1-mediated kidney disease (AMKD)
03

In context

Lead sponsor

Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Part A:

  • APOL1 genotype of G1/G1, G2/G2, or G1/G2
  • Proteinuric kidney disease

Part B:

- Completion of Treatment Period in Part A and no permanent discontinuation of study drug.

Key Exclusion Criteria:

Part A:

  • Solid organ or bone marrow transplant
  • Uncontrolled hypertension
  • History of diabetes mellitus
  • Known underlying cause of kidney disease including but not limited to sickle cell disease

Part B:

  • ESKD (End Stage Kidney Disease) as defined in the protocol.
  • Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.

Other protocol defined Inclusion/Exclusion criteria will apply.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
522 participants (actual)

Study arms

  • Experimental
    Part A (Phase 2/3): VX-147

    Participants will be randomized to receive different doses of VX-147. Participants will receive the selected dose of VX-147 for atleast 96 weeks.

    Drug: VX-147

  • Placebo comparator
    Part A (Phase 2/3): Placebo

    Participants will receive placebo matched to VX-147.

    Drug: Placebo

  • Experimental
    Part B (Phase 3): VX-147

    Participants who complete Part A will receive VX-147 for an additional 96 weeks.

    Drug: VX-147

Interventions

  • DrugVX-147

    Tablets for oral administration.

  • DrugPlacebo

    Tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)

    Time frame: From Baseline to Week 48

  2. Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim Analysis

    Time frame: From Baseline Through >= Week 48

  3. Part A: eGFR Slope Assessed at Final Analysis

    Time frame: From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)

  4. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)

Secondary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)

  2. Part A: Maximum Plasma Concentration (Cmax) of VX-147

    Time frame: Day 1 and Week 40

  3. Part A: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-147

    Time frame: Day 1 and Week 40

  4. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-147

    Time frame: Day 1 up to Week 40

  5. Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4

    Time frame: Day 1 and Week 48

  6. Part B: Percent Change From Baseline in UPCR Over Time

    Time frame: From Baseline Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)

  7. Part B: eGFR Slope Assessment

    Time frame: Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)

07

Study locations

314 sites

Showing the first 100 of 314 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Jun 2028, 74 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 6, 2022
StartActual
Mar 30, 2022
Primary completionEst.
Jun 2, 2028
CompletionEst.
May 7, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
4 sites removed
Show 4 removed
  • Arizona Kidney Disease and Hypertension Center - Banner Desert Office · Mesa, United States
  • MedBio Trials · Miami, United States
  • Nevada Kidney Disease and Hypertension Centers · Las Vegas, United States
  • San Antonio Kidney Disease Center Physicians Group - Medical Center · San Antonio, United States
Oct 15, 2026
Enrollment
466 (estimated)→522 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    4 sites removed
    Show 4 removed
    • Arizona Kidney Disease and Hypertension Center - Banner Desert Office · Mesa, United States
    • MedBio Trials · Miami, United States
    • Nevada Kidney Disease and Hypertension Centers · Las Vegas, United States
    • San Antonio Kidney Disease Center Physicians Group - Medical Center · San Antonio, United States
    Enrollment 466 (estimated)→522 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05312879
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
Mar 30, 2022
Primary completion
Jun 2, 2028 (estimated)
Completion
May 7, 2030 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaxaplin

Start the discussion